Biotech AN2 Therapeutics files for IPO, developing treatment for rare lung disease
By Val Kennedy, Biotech group AN2 Therapeutics (ANTX) has filed to hold an initial public offering to help fund development of its drug candidate for a rare lung disease. The company said it intends to list its stock on the Nasdaq under the symbol ANTX. The size and pricing of the deal were not disclosed in[…]